Purification and Characterization of an Immunomodulatory Peptide from Bovine Placenta Water‐Soluble Extract

Xinping Fang, Wenshui Xia, Quan Z. Sheng, Yuliang WangPreparative 2007 · DOI

TL;DR

Researchers have successfully isolated and characterized a novel immunomodulatory peptide from bovine placenta. This peptide demonstrates a dose-dependent ability to stimulate lymphocyte proliferation and exhibits remarkable thermostability, suggesting its potential as a therapeutic agent.

What Problem Does This Paper Address?

The paper addresses the underutilization of bovine placenta, a byproduct of the dairy industry, which is often discarded and can contribute to environmental contamination. While the placenta is known to contain biologically active compounds, including proteins and peptides with potential therapeutic benefits, specific immunomodulatory agents have not been extensively explored. This study aims to identify, purify, and characterize such a peptide from bovine placenta to explore its potential applications, particularly in modulating immune responses.

Methods

The researchers employed a multi-step purification process involving several chromatography techniques:

  • Ultrafiltration: To separate molecules based on size, specifically isolating fractions less than 10 kDa.
  • DEAE Sepharose CL-6B Chromatography: Anion-exchange chromatography to separate proteins and peptides based on their charge.
  • Sephadex G-25 Gel Filtration Chromatography: Size-exclusion chromatography to further purify based on molecular size.
  • Sephasil C18 Column Chromatography: Reversed-phase high-performance liquid chromatography (RP-HPLC) to separate based on hydrophobicity.

The immune activity of the fractions was assessed using a lymphocyte proliferation assay, specifically the MTT assay, which measures cellular metabolic activity as an indicator of proliferation.

For characterization, the following techniques were used:

  • Capillary Isoelectric Focusing Electrophoresis (CIEFE): To determine the isoelectric point (pI) of the peptide.
  • Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry: To determine the molecular mass of the peptide.
  • Edman Degradation: To determine the N-terminal amino acid sequence.
  • Far-UV Circular Dichroism (CD) Spectroscopy: To assess the secondary structure and thermostability of the peptide.

Datasets

Not discussed in the paper. The study utilized bovine placenta obtained from a dairy company and standard laboratory reagents.

Key Insights and Ideas

  • Bovine Placenta as a Source of Immunomodulatory Peptides: This study highlights the bovine placenta as a valuable, yet largely untapped, source of bioactive peptides with significant immunomodulatory potential.
  • Dose-Dependent Immune Stimulation: The isolated peptide exhibits a clear dose-dependent effect, meaning higher concentrations lead to a stronger stimulation of lymphocyte proliferation, a key indicator of immune system activity.
  • Remarkable Thermostability: The peptide retains a significant portion of its immune activity even after incubation at elevated temperatures (up to 80°C), suggesting it could be robust enough for various processing and storage conditions.
  • Novel Peptide Sequence: The determined N-terminal amino acid sequence (Tyr-X-Phe-Leu-Gly-Leu-Pro-Gly-X-Thr) shows no significant homology with previously identified immunomodulatory peptides, indicating it's a novel discovery.
  • Potential for Therapeutic Applications: The combination of immunomodulatory activity and thermostability makes this peptide a promising candidate for further research into therapeutic applications, such as immune enhancement or treatment of immune-related disorders.

Key Results

  • A purified immunomodulatory peptide was successfully isolated from bovine placenta.
  • The peptide demonstrated a dose-dependent stimulating effect on lymphocyte proliferation.
  • The isoelectric point (pI) of the peptide was determined to be 3.82.
  • The molecular mass of the peptide was found to be 2133.52 Da.
  • The first 10 amino acids of the N-terminal sequence were identified as Tyr-X-Phe-Leu-Gly-Leu-Pro-Gly-X-Thr.
  • The peptide showed no significant homology with known immunomodulatory peptides.
  • The peptide retained approximately 60% of its immune activity after incubation at 80°C for 30 minutes.

Limitations and Future Work

  • Unidentified Amino Acids: The N-terminal sequencing revealed two unidentified amino acids (marked as 'X') within the first 10 residues. Further analysis is needed to fully elucidate the complete amino acid sequence.
  • Presence of Non-Peptide Elements: The authors suggest that the molecular mass determined by mass spectrometry might include non-peptide elements (lipids, carbohydrates) due to difficulties in sequencing. Future work should aim to confirm the peptide moiety and its exact composition.
  • Mechanism of Action: While the peptide stimulates lymphocyte proliferation, the specific cellular and molecular mechanisms underlying this immunomodulatory effect are not detailed and warrant further investigation.
  • In Vivo Studies: The current study focuses on in vitro assays. Future research should involve in vivo studies to evaluate the peptide's efficacy and safety in animal models.
  • Broader Applications: Exploring the peptide's effects on other immune cells and its potential in treating specific immune-related diseases would be valuable next steps.

Summary updated

Abstract

An immunomodulatory peptide was isolated from bovine placenta water-soluble extract and purified by consecutive chromatography on DEAE Sepharose CL-6B, Sephadex G-25, and Sephasil C18 column using lymphocyte proliferation assay to identify the active fractions. The immunomodulatory peptide showed a dose-dependent stimulating effect on lymphocyte proliferation. The isoelectric point of the immunodulatory peptide was determined to be 3.82 by capillary isoelectric focusing electrophoresis. The molecular mass of the immunomodulatory peptide was determined to be 2133.52 Da by mass spectrometry. The first 10 amino acid sequence of the immunomodulatory peptide was Tyr-X-Phe-Leu-Gly-Leu-Pro-Gly-X-Thr. This immunomodulatory peptide showed no significant homology with other immunomodulatory peptides. Additionally, it was thermostable, retaining about 60% of immune activity after incubating at 80 degrees C for 30 min.
BibTeX
@inproceedings{fang2007purification,
  author = {Xinping Fang and Wenshui Xia and Quan Z. Sheng and Yuliang Wang},
  title = {{Purification and Characterization of an Immunomodulatory Peptide from Bovine Placenta Water‐Soluble Extract}},
  booktitle = {Preparative},
  year = {2007},
  doi = {10.1080/10826060701386653},
}
Figure